28,961 Shares in Hims & Hers Health, Inc. (NYSE:HIMS) Bought by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC bought a new stake in Hims & Hers Health, Inc. (NYSE:HIMS) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 28,961 shares of the company’s stock, valued at approximately $700,000.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Crewe Advisors LLC purchased a new stake in shares of Hims & Hers Health during the 4th quarter valued at about $28,000. Raleigh Capital Management Inc. increased its holdings in Hims & Hers Health by 1,100.0% during the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after buying an additional 1,100 shares during the last quarter. Venturi Wealth Management LLC purchased a new stake in Hims & Hers Health during the fourth quarter valued at approximately $48,000. GAMMA Investing LLC raised its position in Hims & Hers Health by 2,173.7% in the fourth quarter. GAMMA Investing LLC now owns 2,251 shares of the company’s stock worth $54,000 after acquiring an additional 2,152 shares during the period. Finally, Principal Securities Inc. boosted its stake in shares of Hims & Hers Health by 48.2% during the 4th quarter. Principal Securities Inc. now owns 3,079 shares of the company’s stock worth $74,000 after acquiring an additional 1,002 shares during the last quarter. 63.52% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, insider Michael Chi sold 17,303 shares of the stock in a transaction on Monday, February 24th. The shares were sold at an average price of $48.14, for a total transaction of $832,966.42. Following the completion of the transaction, the insider now owns 193,601 shares in the company, valued at $9,319,952.14. This trade represents a 8.20 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Andrew Dudum sold 78,127 shares of Hims & Hers Health stock in a transaction on Monday, December 16th. The stock was sold at an average price of $29.62, for a total transaction of $2,314,121.74. Following the completion of the transaction, the chief executive officer now directly owns 109,956 shares of the company’s stock, valued at $3,256,896.72. The trade was a 41.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,062,011 shares of company stock worth $36,892,724 in the last quarter. 17.71% of the stock is owned by corporate insiders.

Hims & Hers Health Stock Performance

Shares of NYSE:HIMS opened at $36.01 on Monday. The firm has a market cap of $8.00 billion, a price-to-earnings ratio of 81.85 and a beta of 1.37. The firm has a fifty day moving average price of $37.64 and a 200 day moving average price of $27.60. Hims & Hers Health, Inc. has a fifty-two week low of $11.20 and a fifty-two week high of $72.98.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, February 24th. The company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business had revenue of $481.14 million during the quarter, compared to the consensus estimate of $494.56 million. As a group, research analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on HIMS shares. Truist Financial upped their price objective on Hims & Hers Health from $24.00 to $39.00 and gave the stock a “hold” rating in a research note on Wednesday, February 26th. TD Cowen restated a “buy” rating and issued a $28.00 price target on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Needham & Company LLC lifted their price objective on Hims & Hers Health from $31.00 to $61.00 and gave the company a “buy” rating in a research report on Tuesday, February 25th. Bank of America reiterated an “underperform” rating and set a $21.00 price objective on shares of Hims & Hers Health in a research note on Thursday. Finally, Piper Sandler raised their target price on shares of Hims & Hers Health from $24.00 to $35.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 25th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, Hims & Hers Health has an average rating of “Hold” and a consensus price target of $37.23.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.